Baghai Thomas C, Schule Cornelius, Zwanzger Peter, Minov Christo, Zill Peter, Ella Robin, Eser Daniela, Oezer Sebnem, Bondy Brigitta, Rupprecht Rainer
Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Nussbaumstrasse 7, D-80336, Munich, Germany.
Neurosci Lett. 2002 Aug 16;328(3):299-303. doi: 10.1016/s0304-3940(02)00527-x.
The Dex/CRH test is one of the most reliable neuroendocrine function tests for hypothalamic-pituitary-adrenocortical (HPA) system dysregulation in depression. Persistent overdrive of HPA system activity after successful antidepressant treatment predicts an enhanced risk for relapse of a depressive episode. As the renin-angiotensin system has been shown to play a role in HPA system activity, we investigated the impact of the angiotensin converting enzyme (ACE) gene insertion (I)/deletion (D) polymorphism, which determines ACE plasma concentrations, on HPA system dysregulation. We performed repeated combined Dex/CRH tests in 115 patients suffering from major depression. Dex/CRH test results were related to the I/D polymorphism within the ACE gene, which was assessed by PCR. Genotype frequencies were comparable to those in the general population (I/I 16.8%, I/D 59.3%, D/D 23.9%). D/D genotypes showed a higher cortisol stimulation during the first Dex/CRH test after admission than homozygous I-allele carriers (repeated measurement ANOVA: P=0.034). Cortisol area under the curve values were highest in those with the D/D genotype (mean+/-SEM [nmol/l*75 min]: 12700+/-2220), intermediate in those with the I/D genotype (9570+/-1000), and lowest in those with the I/I genotype (5160+/-1000; ANOVA: P=0.04). After successful antidepressive treatment and attenuation of HPA system overdrive these differences were no more detectable. The HPA axis stimulating properties of higher ACE and consecutively higher AT-II and/or lower substance P concentrations may be crucial factors for the HPA system hyperactivity during major depressive episodes.
地塞米松/促肾上腺皮质激素释放激素(Dex/CRH)试验是检测抑郁症患者下丘脑-垂体-肾上腺皮质(HPA)系统功能失调最可靠的神经内分泌功能试验之一。抗抑郁治疗成功后,HPA系统活动持续亢进预示着抑郁发作复发风险增加。由于肾素-血管紧张素系统已被证明在HPA系统活动中起作用,我们研究了决定ACE血浆浓度的血管紧张素转换酶(ACE)基因插入(I)/缺失(D)多态性对HPA系统功能失调的影响。我们对115例重度抑郁症患者进行了重复的联合Dex/CRH试验。Dex/CRH试验结果与通过聚合酶链反应(PCR)评估的ACE基因内的I/D多态性相关。基因型频率与普通人群相当(I/I型16.8%,I/D型59.3%,D/D型23.9%)。入院后首次Dex/CRH试验期间,D/D基因型患者的皮质醇刺激水平高于纯合I等位基因携带者(重复测量方差分析:P=0.034)。曲线下皮质醇面积值在D/D基因型患者中最高(平均值±标准误[nmol/l*75分钟]:12700±2220),I/D基因型患者居中(9570±1000),I/I基因型患者最低(5160±1000;方差分析:P=0.04)。抗抑郁治疗成功且HPA系统亢进得到缓解后,这些差异不再明显。较高的ACE以及随之而来的较高的血管紧张素II和/或较低的P物质浓度对HPA轴的刺激特性可能是重度抑郁发作期间HPA系统功能亢进的关键因素。